CoChat

Pharmacological strategies for muscular dystrophy

Khurana, Tejvir S., Davies, Kay E. · 2003 · Nature Reviews Drug Discovery

The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.

Abstract

Duchenne muscular dystrophy (DMD) is a fatal, genetic disorder whose relentless progression underscores the urgency for developing a cure. Although Duchenne initiated clinical trials roughly 150 years ago, therapies for DMD remain supportive rather than curative. A paradigm shift towards developing rational therapeutic strategies occurred with identification of the DMD gene. Gene- and cell-based therapies designed to replace the missing gene and/or dystrophin protein have achieved varying degrees of success. However, pharmacological strategies not designed to replace dystrophin per se appear promising, and can circumvent many hurdles hampering gene- and cell-based therapy. Here, we will review present pharmacological strategies, in particular those dealing with functional substitution of dystrophin by utrophin and enhancing muscle progenitor commitment by myostatin blockade, with a view toward facilitating drug discovery for DMD.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd1085

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Research works printed but not linked: 3

  1. Duchenne, G. B. A. Recherches sur la paralysie musculaire pseudohypertrophique ou paralysie myo-sclerosique. Arch. Gen. Med. 11, 5–528 (1868).
  2. Engel, A. G. & Franzini-Armstrong, C. Myology (McGraw–Hill, New York, 1994).
  3. Bonifati, M. D. et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 23, 1344–1347 (2000). · DOI · Paper page

Cited by

See all 226

Metadata

Authors
Khurana, T. S., & Davies, K. E.
Affiliations
  • University of Pennsylvania (US)
  • University of Oxford (GB)
Corresponding author
Khurana, Tejvir S.
Venue
Nature Reviews Drug Discovery
Published
2003-05-01
Volume
2
Issue
5
Pages
379-390
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2090269652
Cited by
225
References
139
Citations by year
2026: 1 · 2025: 4 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 1 · 2018: 9 · 2017: 4 · 2016: 5 · 2015: 12 · 2014: 12 · 2013: 10 · 2012: 11
FWCI
1.46
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
Funders
Muscular Dystrophy Association
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
Keywords
Duchenne muscular dystrophy, pharmacotherapy, dystrophin, utrophin, muscle progenitor cells, gene therapy, cell therapy, drug discovery, muscle regeneration
MeSH terms
Animals, Calcium, Cytoskeletal Proteins, Disease Models, Animal, Drug Evaluation, Preclinical, Homeostasis, Humans, Membrane Proteins, Muscular Dystrophies, Promoter Regions, Genetic, Drug Design, Dystrophin, Utrophin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.